REUTERS/Christinne Muschi
Michael Pearson, chairman of the board and chief executive officer of Valeant Pharmaceuticals International Inc, poses following their annual general meeting in Laval, Quebec May 19, 2015.
Valeant's stock collapsed last year under the weight of federal investigations into its pricing practices, allegations of accounting irregularities from a short seller, and the revelation of its secret, close relationship with Philidor - a pharmacy that is also now under investigation for questionable practices with insurance claims.
Valeant's stock is down over 3% in after hours trading on this news.